Targeting EGFR–REM2–Ca2+ signaling and LDHA: amphiregulin remodels energy metabolism to enhance aged embryo development Authors: Dandan Yang, Menghan Chai, Kuanjian Zhang, Qiqi Zhang, Chao Zhang, Huijuan Zou, Weiwei Zou, Lanxin Xie, Min Xiong, Tingting Ye, Beili Chen, Zhiguo Zhang Published: 2025 ABSTRACT AbstractAdvances in assisted reproductive technology (ART) have expanded treatment options for many infertile families. However, outcomes in women of advanced maternal age remain suboptimal, primarily due to fewer retrievable oocytes and diminished embryonic developmental competence. In this study, we show that adding an appropriate concentration of amphiregulin (AREG) to the embryo culture medium significantly enhances the developmental competence of embryos from aged mice. Mechanistically, AREG binds to the epidermal growth factor receptor and induces receptor phosphorylation, thereby upregulating Ras like protein REM2. REM2 suppresses voltage gated calcium channel–mediated Ca2+ influx, reducing the elevated Ca2+ levels observed in aged embryos relative to young embryos and maintaining ATP supply. The improvement in ATP levels, in turn, restrains the excessive expression of LDHA in aged embryos, thereby decreasing pyruvate to lactate conversion and global protein lactylation, ultimately shifting embryonic physiology toward a more youthful state. These findings support supplementation with AREG during embryo culture as a rational strategy to improve ART outcomes in women of advanced maternal age.Supplementary InformationThe online version contains supplementary material available at 10.1007/s00018-025-06037-5.Keywords: Amphiregulin, Advanced maternal age, Embryo culture, Ca2+ homeostasis, LDHA, Lactylation Introduction With socioeconomic development, delayed marriage and childbearing are increasingly prevalent, leading to a general postponement of reproductive age and adversely affecting pregnancy outcomes and the long-term health of offspring [1, 2]. Female natural conception rates begin to decline at 31–35 years, and approximately one-third of women aged 35–39 experience reduced fertility [3]. Against this backdrop, the use of assisted reproductive technology (ART) has increased to address age-related infertility [4]. However, ART cannot reverse ovarian aging, and in vitro fertilization (IVF) outcomes remain strongly age-dependent: women aged 25–30 years achieve the highest live-birth rates, and after age 30 these rates decrease by approximately 1.5% per year; advanced maternal age has therefore become a leading cause of IVF failure [5–7], accompanied by decreased oocyte yield and quality, reduced embryonic developmental competence, and increased aneuploidy [8–13]. Current strategies—including in vitro activation, oocyte cryopreservation, ovarian tissue transplantation, and various culture medium interventions—primarily aim to increase oocyte yield and reduce aneuploidy [14–17]. Despite these efforts, the live-birth rate per oocyte continues to decline with age [18], indicating the need to develop embryo stage-specific culture protocols for women of advanced maternal age. Amphiregulin (AREG), a ligand of the epidermal growth factor receptor (EGFR), activates multiple signaling pathways (e.g., RAS–RAF–MEK–ERK and PI3K–AKT) [19–24]. It is expressed in multiple human tissues, with the highest levels in the ovary and placenta. Although Areg knockout mice remain fertile, they exhibit impaired ovarian function [24–26]. AREG plays a key role in oocyte maturation and ovulation; cross-species studies of in vitro maturation (IVM) show that it can enhance oocyte developmental competence and maturation rates [27–32]. In addition, AREG may function as an autocrine factor in early embryos, promoting blastocyst formation and increasing cell numbers [33]. Based on this evidence, we supplemented the in vitro embryo culture of aged mice with a defined concentration of AREG to evaluate whether it improves the developmental competence of aged embryos. Materials and methods Case collection We collected IVF patient cases treated at the Reproductive Medicine Center of the First Affiliated Hospital of Anhui Medical University from 2015 to 2025. This study received approval from the Ethics Committee of Anhui Medical University (No. 20240111). All participants provided written informed consent for the use of their clinical data in this research. Mouse husbandry All animal procedures were approved by the Animal Ethics Committee of Anhui Medical University (No: LLSC20242465). Young (approximately 6–8 weeks old) and aged (approximately 11–12 months old) female C57BL/6 mice were maintained under a 12 h light/12 h dark cycle at a constant temperature, with ad libitum access to food and water. Superovulation, in vitro fertilization, and embryo culture Female mice received 10 IU pregnant mare serum gonadotropin (PMSG), followed 48 h later by 10 IU human chorionic gonadotropin (hCG). At 14–16 h post‑hCG, oviductal ampullae were collected and oocyte—cumulus complexes (COCs) released into HTF under oil. Sperm from the cauda epididymides of two 10–15‑week C57 males were released into TYH under oil and capacitated for 1 h at 37 °C, 5% CO₂. Capacitated sperm were added to COCs in HTF. Six hours post‑insemination, zygotes were washed and transferred to KSOM for culture at 37 °C, 5% CO₂. Embryos reached the 2‑cell stage at ~ 18 h and the 4–8‑cell stage at ~ 45 h. Live cell staining MitoTracker Green (Beyotime Biotechnology; C1048; 1:1000) was used to assess mitochondrial content in embryos; tetramethylrhodamine methyl ester (TMRM) (Thermo Fisher; T669; 1:1000) to evaluate mitochondrial membrane potential; BODIPY™ FL ATP (Thermo Fisher; A12410; 1:1000) to measure ATP content; and Fluo‑4 AM (Beyotime Biotechnology; S1061M; 1:1000) to detect intracellular Ca2+ levels. ATP and lactate quantification ATP levels were measured using an Enhanced ATP Assay Kit (Beyotime Biotechnology; S0026). After three PBS washes, 30 embryos were placed into a PCR tube containing 20μL ATP lysis buffer. ATP working solution was added to a black 96‑well plate and incubated at room temperature for 5 min; samples were then transferred into each well and mixed thoroughly. Luminescence was recorded with a luminometer, and ATP content was calculated by linear regression against an ATP standard curve. Experiments were repeated three times. L‑lactate levels were measured using an L‑Lactate Assay Kit (Solarbio, Beijing; BC2235). 10 embryos were placed into a PCR tube containing 20μL lysis buffer. Following the manufacturer’s instructions, absorbance was measured at 570 nm on a microplate reader, and lactate content was calculated according to the provided formula. Experiments were repeated three times. Immunofluorescence confocal microscopy for detecting target protein expression in embryos Embryos were fixed in 4% paraformaldehyde for 1 h, washed three times in PBS to remove residual fixative, permeabilized in 5% saponin for 30 min, and blocked in 5% BSA for 1 h. Primary antibodies: CDX2: Abcam, ab76541; RRAD And GEM Like GTPase 2 (REM2): Thermo Fisher, PA5‑103871; lactate dehydrogenase A (LDHA) and lactate dehydrogenase B (LDHB): Proteintech, 21799‑1‑AP and 14824‑1‑AP; pan‑lactylation: PTM BIO, PTM‑1401RM; p‑EGFR: Abcam, ab40815) were diluted 1:500. Twenty‑microliter drops of the diluted primary antibody solution were dispensed onto glass‑bottom dishes and overlaid with mineral oil; embryos were placed in the droplets and incubated overnight at 4 °C. Unbound primary antibody was removed by PBS washes, followed by light‑protected incubation for 1 h with the corresponding fluorophore‑conjugated secondary IgG antibodies. After PBS washes to remove unbound secondary antibody, samples were counterstained with DAPI for 10 min. Finally, embryos were placed in small drops on glass‑bottom observation dishes and imaged using a laser‑scanning confocal microscope. For quantification, confocal Z‑stacks were acquired with identical laser power, gain, and offset settings across all groups within each experiment. Maximum‑intensity projections were generated, and a region of interest encompassing the entire embryo was defined. Mean fluorescence intensity per embryo was then calculated after background subtraction using adjacent cell‑free regions. All fluorescence images were processed and quantified using ZEN software (Carl Zeiss). Low‑input transcriptome sequencing 2-cell and 4–8-cell embryos were collected from the Young, Aged, and Aged + AREG treatment groups (from 3 young and 3 aged mice). After removal of the zona pellucida, embryos from each group were placed into PCR tubes containing 2μL single‑cell lysis buffer. Samples were sent to BGI for low‑input transcriptome sequencing. Statistics and reproducibility In all embryo‑based analyses, n refers to the number of embryos. For each independent experiment, young embryos were derived from 3 young female mice, and embryos from 3 aged female mice were collected and evenly distributed into the Aged and Aged + AREG groups. All measurements for each parameter were repeated in at least three independent experiments. Statistical analyses were performed using GraphPad Prism 8.0. Categorical variables were analyzed using the chi‑square test or Fisher’s exact test. For continuous variables, after testing for normality, two‑group comparisons were performed using two‑tailed unpaired t‑tests; for three‑group comparisons, one‑way analysis of variance with Bonferroni post hoc multiple comparisons was applied. All tests were two‑sided and conducted at a significance level of P < 0.05. All presented data are from at least three independent experiments. Results Embryonic developmental competence is significantly reduced in advanced maternal age compared with young We analyzed IVF cycles from advanced maternal age (age ≥ 35 years) patients between May 2019 and July 2025, totaling 6,984 oocyte-retrieval cycles. As 1–12 oocytes were retrieved in > 90% of cycles (Fig. 1a), comparisons between aged and young cohorts were restricted to this range. Fertilization and cleavage rates were comparable between groups; however, the high-quality embryo rate, blastocyst rate, and high quality blastocyst rate were significantly lower in the aged group (Fig. 1b–f; Supplementary Table 1). These findings indicate reduced embryonic developmental competence in women of advanced maternal age despite similar oocyte yield and zygote numbers, underscoring the need to optimize embryo stage culture protocols for women of advanced maternal age. Embryo development in young women and in women of advanced maternal age (> = 35 years old) with the same number of oocytes retrieved. This figure compares developmental outcomes between groups across oocyte retrieval counts ranging from 1 to 12 after in vitro fertilization. a Distribution of women of advanced maternal age across oocyte retrieval categories from 2017 to 2025. b Comparison of fertilization rates between groups for 1–12 oocytes retrieved. c Comparison of cleavage rates between groups for 1–12 oocytes retrieved. d Comparison of high-quality embryo rates between groups for 1–12 oocytes retrieved. e Comparison of blastocyst formation rates between groups for 1–12 oocytes retrieved. f Comparison of high-quality blastocyst rates between groups for 1–12 oocytes retrieved Optimal working concentration of AREG During IVF, oocytes and sperm were co-incubated in HTF for 5 h; zygotes were then cultured in KSOM to blastocyst. To assess AREG effects in aged embryos, KSOM was supplemented with graded AREG concentrations. 100 nM AREG significantly increased 4–8-cell, morula, and blastocyst formation rates in aged mice and elevated blastocyst total cell number (Supplementary Fig. 1a–d; Supplementary Table 2). Thus, 100 nM was selected as the working concentration for subsequent experiments. AREG promotes embryonic development during IVF in aged mice To further evaluate the effect of 100 nM AREG on embryonic development in aged mice, we established three groups: Young (KSOM), Aged (KSOM), and Aged + AREG (KSOM containing 100 nM AREG) (Fig. 2a). The 2-cell rates did not differ among the three groups, indicating no effect on fertilization or the first cleavage. However, the formation rates of 4–8-cell embryos, morulae, and blastocysts were significantly higher in both the Young and Aged + AREG groups than in the Aged group (Fig. 2b and c and Supplementary Table 3). Moreover, both total blastocyst cell number and the number of inner cell mass (ICM) cells were significantly higher in the Young and Aged + AREG groups than in the Aged group (Fig. 2d and e), indicating that AREG supplementation rescues age‑related deficits and improves embryonic developmental competence. AREG intervention restores the developmental potential of aged embryos. a Schematic of the experimental design for AREG treatment during in vitro culture. Zygotes in the Young and Aged groups were cultured in KSOM, whereas the Aged + AREG group was cultured in KSOM supplemented with 100 nM AREG. b Representative images of embryo development in the three groups, scale bars: 50 μm. c Quantification of embryo developmental outcomes across the three groups (Young: n = 100; Aged: n = 109; Aged + AREG: n = 107). d Representative images of blastocysts from the three groups; CDX2 immunostaining was used to label trophectoderm cells, scale bars: 20 μm. e Quantification of blastocyst cells (Young: n = 12; Aged: n = 12; Aged + AREG: n = 12). Statistics: Data in panel (c) were analyzed using a chi-square test. Data in panel (e) were analyzed using one-way ANOVA with Bonferroni post hoc multiple comparisons. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, ns: not significant. All data are from at least three independent experiments AREG improves the viability of aged embryos In IVF outcomes, the 4–8-cell/2-cell ratio and the morula/4–8-cell ratio were significantly higher in the Young and Aged + AREG groups than in the Aged group, whereas the blastocyst/morula ratio did not differ significantly among the three groups (Supplementary Table 3), suggesting that AREG primarily promotes progression to the blastocyst stage during the 2 to 8-cell window. Mitochondria are the most abundant and functionally pivotal organelles in early embryos. Their dysfunction—manifested as reduced cellular respiration and electron transport efficiency, leading to decreased ATP production—is considered an important contributor to preimplantation developmental delay or arrest [34]. Compared with young mice, embryos from aged mice at the 2–8-cell stages exhibited significantly reduced mitochondrial abundance and membrane potential (as indicated by the live-cell probes MitoTracker and TMRE); with AREG supplementation, these indices were restored toward youthful levels (Fig. 3a–d). Prior studies have established that Ca2+ homeostasis is crucial for oocyte activation and embryonic development [35, 36]. Using Fluo 4 AM to quantify intracellular Ca2+ levels, we found that aged 2-cell embryos displayed significantly higher Ca2+ than the young group, which was reduced by AREG intervention (Fig. 3e). At the 4–8-cell stage, this difference in intracellular Ca2+ levels was no longer significant (Fig. 3f). Moreover, measurements using BODIPY™ FL ATP and an ATP assay kit both demonstrated that AREG supplementation increased ATP levels in early embryos from aged mice (Fig. 3g and h). AREG intervention improves the bioenergetic function of aged embryos. a Representative images of mitochondrial content at the 2-cell stage in the three groups, with quantification of fluorescence intensity (Young: n = 14; Aged: n = 13; Aged + AREG: n = 13). b Representative images of mitochondrial content at the 8-cell stage in the three groups, with quantification of fluorescence intensity (Young: n = 16; Aged: n = 14; Aged + AREG: n = 14). c Representative images of mitochondrial membrane potential at the 2-cell stage in the three groups, with quantification of fluorescence intensity (Young: n = 19; Aged: n = 18; Aged + AREG: n = 18). d Representative images of mitochondrial membrane potential at the 8-cell stage in the three groups, with quantification of fluorescence intensity (Young: n = 23; Aged: n = 17; Aged + AREG: n = 17). e Representative images and quantification of fluorescence intensity for Ca2+ levels at the 2-cell stage across the three groups (Young: n = 19; Aged: n = 23; Aged + AREG: n = 23). f Representative images and quantification of fluorescence intensity for Ca2+ levels at the 4–8-cell stage across the three groups (Young: n = 18; Aged: n = 16; Aged + AREG: n = 16). g Representative images of ATP content at the 2-cell stage in the three groups, with quantification of fluorescence intensity (Young: n = 19; Aged: n = 15; Aged + AREG: n = 15); mean ATP content at the 2-cell stage across the three groups (three assays, 30 embryos per group per assay). h Representative images of ATP content at the 4–8-cell stage in the three groups, with quantification of fluorescence intensity (Young: n = 18; Aged: n = 15; Aged + AREG: n = 17); mean ATP content at the 4–8-cell stage across the three groups (three assays, 30 embryos per group per assay). Statistics: Data were analyzed using one-way ANOVA with Bonferroni post hoc multiple comparisons. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05. All data are from at least three independent experiments. Scale bars, 20 µm Collectively, supplementation with AREG during in vitro culture significantly mitigates age-related impairment of embryonic viability, with a principal window of action between the 2 and 8-cell stages, likely by improving mitochondrial function and maintaining Ca2+ homeostasis to enhance energy metabolism and developmental potential. AREG maintains Ca2+ homeostasis in aged embryos by upregulating REM2 To elucidate how AREG enhances the viability of aged embryos, we performed microtranscriptomic sequencing on three groups of embryos at the mid-2-cell stage. Heatmap analyses revealed pronounced transcriptomic differences between 2-cell embryos from young and aged mice, whereas AREG treatment partially restored the transcriptomic profile of aged embryos (Fig. 4a). Relative to untreated aged embryos, 8 transcripts were upregulated and 3 were downregulated in the AREG group (Fig. 4b). Literature review and functional annotation indicated that REM2, one of the upregulated genes, has GTP-binding activity (Fig. 4c and d) and inhibits voltage gated calcium channel (VGCC)–mediated Ca2+ influx. REM2 is recognized as an important regulator of pluripotency maintenance during early embryogenesis and of neuronal survival during later embryonic development [34, 37]. AREG intervention reduces intracellular Ca2+ levels in aged embryos. a Heatmap of all differentially expressed genes (DEGs) in 2-cell embryos from young mice, aged mice, and AREG-treated aged mice. b Heatmap of DEGs in 2-cell embryos from aged mice versus AREG-treated aged mice. c RNA-seq analysis of the selected DEG REM2 in the Aged and Aged + AREG groups. d Immunofluorescence validation of REM2 expression levels in 2-cell embryos across the three groups (Young: n = 10; Aged: n = 10; Aged + AREG: n = 10), scale bars: 10 μm. e During IVF, representative images and fluorescence-based quantification of intracellular Ca2+ at the zygote stage, pre–2-cell division, 2-cell stage, pre–4-cell division, and 4-cell stage (10 embryos per group), scale bars: 20 μm. f Immunofluorescence validation of REM2 expression levels(Aged: n = 10; Aged + AREG: n = 10; Aged + AREG + PMA: n = 10) and intracellular Ca2+ levels(Aged: n = 10; Aged + AREG: n = 10; Aged + AREG + PMA: n = 10) in 2-cell embryos across the four groups, scale bars: 10/20 μm. g Representative images of developmental progression from the 2-cell stage and comparison of the 4–8-cell rate among groups (Aged: n = 48; Aged + AREG: n = 49; Aged + AREG + PMA: n = 49). Red circle: 2-cell embryo with developmental arrest, scale bars: 50 μm. Statistics: Data in panels (d–f) were analyzed using one way ANOVA with Bonferroni post hoc multiple comparisons. Data in panel (g) were analyzed using a chi square test. ****P < 0.0001, *P < 0.05, ns: not significant. All data are from at least three independent experiments Ca2+ participates in key processes including energy production, chromosome segregation, pronucleus formation, and gene expression. Excess cytosolic Ca2+ disrupts mitochondrial oxidative phosphorylation; thus, mitochondrial Ca2+ uptake and release must remain dynamically balanced within a homeostatic range [35, 36]. Impaired Ca2+ homeostasis is a major cause of early embryonic developmental failure. Although Ca2+ oscillations at fertilization have been extensively studied [36], the Ca2+ dynamics at the mid-2-cell stage are poorly characterized. Using Fluo-4 AM to quantify cytosolic Ca2+ in young embryos, we observed pronounced Ca2+ elevations immediately prior to cleavage (pre-2-cell and pre-4-cell), with lower and relatively stable levels at other time points (Fig. 4e). Compared with young embryos, aged 2-cell embryos exhibited overall higher Ca2+ levels (Fig. 3e), deviating from the physiological “low-and-stable” state. This suggests that disrupted Ca2+ homeostasis in aged embryos compromises mitochondrial energy supply and thereby weakens developmental potential. By upregulating REM2, AREG suppresses Ca2+ influx, reduces cytosolic Ca2+ at the 2-cell stage, and improves developmental potential. To verify this mechanism, zygotes from aged mice were exposed to an appropriate concentration of the REM2 inhibitor phorbol 12-myristate-13-acetate (PMA) (Supplementary Fig. 2a—b) and co-cultured with AREG. In the AREG-only group, REM2 expression in 2-cell embryos was significantly upregulated and the intracellular Ca2+ concentration was decreased. By contrast, in embryos co-cultured with PMA and AREG, REM2 expression was significantly lower than in the AREG-only group, whereas the intracellular Ca2+ concentration was significantly higher (Fig. 4f). Furthermore, when PMA-treated zygotes were cultured to day 3, the number of embryos reaching the 4–8-cell stage was markedly reduced, and AREG failed to rescue this developmental defect (Fig. 4g). Collectively, these findings support that AREG maintains Ca2+ homeostasis in aging embryos by upregulating REM2; once REM2 expression is inhibited, the AREG-mediated restoration of Ca2+ homeostasis is abrogated. Further, fertilized oocytes from young mice were cultured in KSOM or KSOM + AREG to the 2-cell stage, followed by treatment with the Ca2+ ionophore ionomycin for a subset of KSOM embryos and for all KSOM + AREG embryos (Supplementary Fig. 3a–d and Fig. 5a). Ionomycin rapidly elevated cytosolic Ca2+; after 10 min, embryos in the AREG group were the first to recover to near-control levels (Fig. 5b). REM2 expression analysis across the three groups confirmed that AREG significantly upregulated REM2 (Fig. 5c). Functionally, ionomycin significantly reduced embryonic ATP levels, whereas culture with AREG mitigated this decline (Fig. 5d). When ionomycin-treated 2-cell embryos were cultured to the next day, the proportion developing to the 4–8-cell stage was significantly lower than in controls; under AREG conditions, however, this adverse effect was effectively prevented (Fig. 5e). Intracellular Ca2+ levels at the 2-cell stage influence embryo development. a Schematic of the ionomycin intervention in 2-cell embryos. Control: 2-cell embryos cultured in KSOM; Iono-T: 2-cell embryos cultured in KSOM treated with ionomycin; Iono-T + A: 2-cell embryos cultured in ionomycin-treated KSOM supplemented with AREG. b Representative images and quantification of fluorescence intensity for intracellular Ca2+ levels at post-treatment time points of 0, 5, and 10 min (Control: n = 12; Iono-T: n = 12; Iono-T + A: n = 12), scale bars: 20 μm. c Representative images and quantification of fluorescence intensity for REM2 expression levels across groups (Control: n = 10; Iono-T: n = 10; Iono-T + A: n = 10), scale bars: 10 μm. d Representative images and quantification of fluorescence intensity for ATP levels across groups (Control: n = 13; Iono-T: n = 12; Iono-T + A: n = 12), scale bars: 20 μm. e Representative images of developmental progression from the 2-cell stage and comparison of the 4–8-cell rate among groups (Control: n = 40; Iono-T: n = 42; Iono-T + A: n = 40). Red circle: 2-cell embryo with developmental arrest, scale bars: 50 μm. Statistics: Data in panels (b–d) were analyzed using one-way ANOVA with Bonferroni post hoc multiple comparisons. Data in panel (e) were analyzed using a chi-square test. ****P < 0.0001, ***P < 0.001, ns: not significant. All data are from at least three independent experiments In sum, at the 2-cell stage AREG upregulates REM2 to suppress VGCC-mediated Ca2+ influx, restore and maintain Ca2+ homeostasis, promote ATP production, and ultimately enhance the early developmental potential of aged embryos. Inhibition of REM2 reverses the beneficial effects of AREG, highlighting REM2 as a key effector of AREG action and a potential therapeutic target. AREG improves aged embryo development by reducing LDHA In our preceding experiments, we demonstrated that, at the 2-cell stage, aged embryos exhibit disrupted Ca2+ homeostasis that reduces ATP supply, thereby limiting progression to the 4–8-cell stage. However, once aged 2-cell embryos successfully reach the 4–8-cell stage, the differences in Ca2+ dynamics are no longer evident (Fig. 3f), that is, aged embryos at the 4–8-cell stage maintain a low and relatively stable Ca2+ state comparable to young embryos. Nevertheless, the ATP content of aged 4–8-cell embryos remains lower than that of age-matched young embryos, and AREG exerts a beneficial effect during this period by enabling more aged 4–8-cell embryos to progress to the next stage. These observations indicate that, in addition to restoring Ca2+ homeostasis at the 2-cell stage via upregulation of Ras-like protein REM2, AREG engages additional mechanisms to enhance embryonic energy supply. Thus, to further investigate how AREG improves embryonic development in aged embryos, we performed microtranscriptomic sequencing on embryos at the 4–8-cell stage across the three groups and found that LDHA was significantly upregulated in the Aged group, whereas its levels were lower in the Young and AREG-treated groups (Fig. 6a). Immunofluorescence confirmed that AREG treatment significantly reduced LDHA expression in 2–8-cell embryos (Fig. 6b–c). LDHA catalyzes the terminal step of glycolysis—reducing pyruvate to lactate while oxidizing NADH to NAD+ (Fig. 6d). Upregulated LDHA diverts more cytosolic pyruvate to lactate, while the expression of lactate dehydrogenase B (LDHB), which oxidizes lactate to pyruvate, showed no significant change in embryos (Fig. 6e). Consequently, substrate availability for oxidative phosphorylation (OXPHOS) is diminished and lactate accumulates (Fig. 6f). AREG reduces LDHA and pan-lactylation levels in early embryos from aged females. a Expression of LDHA transcript levels in 4–8-cell embryos from young mice, aged mice, and AREG-treated aged mice. b Representative images of LDHA expression in 2-cell embryos across the three groups and quantification of fluorescence intensity (Young: n = 15; Aged: n = 15; Aged + AREG: n = 15), scale bars: 10 μm. c Representative images of LDHA expression in 4–8-cell embryos across the three groups and quantification of fluorescence intensity (Young: n = 19; Aged: n = 17; Aged + AREG: n = 17), scale bars: 10 μm. d Schematic diagram of the mechanistic role of LDHA. e Representative images of LDHB expression in embryos across the three groups and quantification of fluorescence intensity (Young: n = 8; Aged: n = 8; Aged + AREG: n = 8), scale bars: 10 μm. f Mean lactate content at the 2–8-cell stages across the three groups (three assays, 10 embryos per group per assay). g Representative images of pan-lactylation levels in embryos across the three groups and quantification of fluorescence intensity (2-cell: Young: n = 35; Aged: n = 20; Aged + AREG: n = 21. 4–8-cell: Young: n = 23; Aged: n = 16; Aged + AREG: n = 16), scale bars: 10 μm. h Representative images of embryo development in each group and quantification of developmental outcomes. Y: Young + KSOM; YG: Young + KSOM + GSKA; A: Aged + KSOM; AG: Aged + KSOM + GSKA; AP: Aged + KSOM + pyruvate (Y: n = 52; YG: n = 52; A: n = 57; AG: n = 58; AP: n = 58), scale bars: 50 μm. i Representative images of LDHA expression in 2–8-cell embryos in each group and quantification of fluorescence intensity (10 embryos per group), scale bars: 10 μm. j Representative images of pan-lactylation levels in 2–8-cell embryos in each group and quantification of fluorescence intensity (10 embryos per group), scale bars: 10 μm. k Representative images of ATP levels in 2–8-cell embryos in each group and quantification of fluorescence intensity (2-cell: Y: n = 18; YG: n = 15; A: n = 14; AG: n = 13; AP: n = 15. 4–8-cell: Y: n = 15; YG: n = 11; A: n = 10; AG: n = 14; AP: n = 15), scale bars: 20 μm. Statistics: Data in panel (h) were analyzed using a chi-square test. All other quantitative data were analyzed using one-way ANOVA with Bonferroni post hoc multiple comparisons. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05, ns: not significant. All data are from at least three independent experiments Recent breakthrough studies have shown that lactate serves as a substrate for histone lactylation, a modification indispensable for regulating zygotic genome activation and likely involved more broadly in maintaining stem-cell pluripotency, adaptation to hypoxia, and modulation of embryonic developmental potential and implantation [38–40]. To examine lactylation in early embryos, we used a pan-lactylation antibody to quantify intracellular pan-lactylation levels. During the 2–8-cell stages, pan-lactylation was significantly higher in aged embryos than in young embryos (Fig. 6g), and AREG treatment significantly reduced this elevation. While lactylation is crucial for embryonic development, we hypothesized that excessively high lactylation in aged embryos may impair developmental capacity. We further posited that reduced cytosolic pyruvate in aged embryos compromises OXPHOS and thereby decreases ATP synthesis. To dissect causality, we added 1 µM LDHA inhibitor GSK2837808A (GSKA) to KSOM to inhibit LDHA in young embryos (YG) and aged embryos (AG) (Supplementary Fig. 4a–b). The KSOM used contained 0.2 mM pyruvate; in a subset of aged‑embryo cultures we increased pyruvate to 0.3 mM (AP). In vitro culture showed that in young embryos, GSKA significantly reduced the formation rates of 4–8-cell embryos, morulae, and blastocysts, whereas in aged embryos both GSKA and pyruvate supplementation increased the formation rates of 4–8-cell embryos, morulae, and blastocysts (Fig. 6h and Supplementary Table 4). Immunofluorescence demonstrated that GSKA significantly reduced LDHA expression and pan‑lactylation in both young and aged embryos (Fig. 6i–j). Under GSKA treatment, ATP content declined significantly in Young 2–8-cell embryos, whereas in Aged embryos ATP content at the 2-cell stage was unchanged and in 4–8‑cell embryos it slightly increased; moreover, pyruvate supplementation increased ATP content in aged 2–8- cell embryos (Fig. 6k). Together, these results indicate that appropriate LDHA expression and histone pan‑lactylation are required for early embryonic development. By lowering excessive LDHA expression in aged embryos, AREG decreases pyruvate‑to‑lactate conversion, thereby reducing excessive pan‑lactylation and increasing ATP synthesis via OXPHOS, ultimately improving the developmental potential of aged embryos. Imbalance of Ca2+ homeostasis upregulates LDHA in embryos Early embryos typically reside in a relatively hypoxic environment and undergo very rapid cell divisions, which demand ATP [41]. As noted above, Ca2+ homeostasis is disrupted at the 2-cell stage in aged mice, impairing ATP production. To compensate, embryos may upregulate LDHA to increase NAD+ regeneration, thereby potentially boosting glycolytic flux to sustain the ATP required for rapid development. To test this hypothesis, we stimulated a subset of young 2-cell embryos with the calcium ionophore ionomycin and assessed LDHA expression and pan‑lactylation during the 2–8-cell stages. LDHA and pan‑lactylation were significantly increased in ionomycin‑stimulated 2-cell embryos (Fig. 7a–b). These data suggest that at the 2-cell stage, disruption of Ca2+ homeostasis and the associated ATP decline upregulate LDHA and enhance pan‑lactylation. In contrast, AREG treatment upregulates REM2 to maintain calcium homeostasis in aged 2-cell embryos, limiting ATP loss and thereby preventing this compensatory response. Disruption of intracellular Ca2+ homeostasis in early embryos upregulates LDHA and pan-lactylation. a Representative images of LDHA expression in young 2-cell embryos versus ionomycin-treated young 2-cell embryos, with quantification of fluorescence intensity (Control: n = 15; Iono-T: n = 15). b Representative images of pan-lactylation (pan-lactylation) in the two groups of 2-cell embryos, with quantification of fluorescence intensity (Control: n = 15; Iono-T: n = 15). c Representative images of LDHA expression in 4–8-cell embryos in the two groups, with quantification of fluorescence intensity (Control: n = 12; Iono-T: n = 13). d Representative images of pan-lactylation in 4–8-cell embryos in the two groups, with quantification of fluorescence intensity (Control: n = 12; Iono-T: n = 12). Statistics: Data were analyzed using one way ANOVA with Bonferroni post hoc multiple comparisons. **P < 0.01, *P < 0.05, ns: not significant. Scale bars, 10 µm. All data are from at least three independent experiments Among embryos in the ionomycin group that progressed to the 4–8-cell stage, LDHA expression and pan‑lactylation were comparable to controls (Fig. 7c–d). As noted earlier, ionomycin treatment increases the proportion of embryos arrested at the 2-cell stage (Fig. 5e). However, those young embryos that successfully advance to the 4–8-cell stage may overcome the transient Ca2+ instability through intrinsic compensatory mechanisms. Consequently, they do not exhibit further glycolytic upregulation due to energy shortfall, and LDHA is not elevated. AREG upregulates REM2 by inducing EGFR phosphorylation To elucidate how AREG regulates REM2, prior studies indicate that REM2 belongs to the RGK family of Ras‑related small GTPases [34], and that AREG, an EGFR ligand, binds EGFR to induce its phosphorylation, thereby modulating RAS‑pathway signaling [24]. We therefore hypothesized that, in our system, AREG upregulates REM2 by inducing EGFR phosphorylation. To test this, we added the EGFR inhibitor osimertinib to the culture medium of a subset of aged embryos within the AREG‑treated group and assessed phosphorylated EGFR (p‑EGFR) and REM2 expression across groups. In aged embryos, AREG treatment robustly induced EGFR phosphorylation and increased REM2 expression, whereas in the osimertinib group EGFR phosphorylation was markedly inhibited and REM2 was not upregulated relative to the aged control (Fig. 8a). These results support that AREG upregulates REM2 expression via EGFR phosphorylation. AREG induces EGFR phosphorylation to upregulate REM2 in early embryos. a Representative images of phospho-EGFR (p-EGFR) and REM2 expression across four groups—Young, Aged, Aged treated with AREG, and Aged co-treated with AREG and osimertinib—with quantification of fluorescence intensity. Statistics: Data in panel (a) were analyzed using one way ANOVA with Bonferroni post hoc multiple comparisons. ****P < 0.0001, ns: not significant. b Schematic summarizing how AREG promotes the in vitro development of early embryos from aged mice In summary, during embryo culture, AREG acts by binding to the EGFR and inducing its phosphorylation, thereby upregulating Ras-like protein REM2 and inhibiting voltage-gated calcium channels. This reduces cytosolic Ca2+ levels in aged embryos and maintains calcium homeostasis, thereby promoting ATP production. Consequently, the excessive expression of LDHA is restrained, pyruvate-to-lactate conversion is reduced, and excessive protein lactylation is attenuated, shifting the embryonic state toward that of young embryos. Collectively, these actions remodel early embryonic energy metabolism and ultimately enhance the developmental potential of aged embryos (Fig. 8b). Discussion Suboptimal IVF outcomes in women of advanced maternal age are primarily attributable to declines in both oocyte quantity and quality, together with increased rates of embryonic aneuploidy. Although current strategies focus largely on improving in vitro maturation and reducing aneuploidy, the cleavage stage within the IVF workflow is equally critical; optimization of this window may effectively mitigate age-related declines in female fertility. Early embryonic cleavage progresses rapidly and is highly dependent on energy supply. In oocytes and embryos from aged patients, ATP insufficiency commonly coexists with intracellular Ca2+ dysregulation [42], and we likewise observed elevated Ca2+ levels in aged 2-cell embryos. Ca2+ homeostasis and energy metabolism interact bidirectionally: ATP both maintains Ca2+ homeostasis and is influenced by it [43]. Disruption of both systems synergistically undermines developmental potential. Early embryos rely on both OXPHOS and glycolysis, but the stage at which glycolysis becomes predominant remains debated [44, 45]. Meanwhile, the age-related decline of NAD+ in oocytes may lead to relative insufficiency at the embryonic stage [46], inducing upregulation of LDHA to regenerate NAD+ and increase glycolytic flux [47]. However, excessive glycolysis is associated with poorer blastocyst formation and reduced post-transfer viability [48, 49], suggesting that this putative compensatory response may be detrimental. LDHA upregulation diverts pyruvate toward lactate, elevating lactylation levels that may perturb zygotic genome activation and epigenetic reprogramming; simultaneously, diversion of pyruvate limits substrates for OXPHOS, further decreasing ATP and exacerbating developmental arrest. Collectively, these metabolic shifts align with the 'quiet embryo' hypothesis, which posits that embryos with a more ‘quiet’ metabolic profile exhibit greater developmental competence, whereas a highly ‘active’ metabolic state often reflects cumulative stress and damage [50]. In aged embryos, elevated cytosolic Ca2⁺, LDHA upregulation, increased pyruvate to lactate conversion, and excessive pan-lactylation are indicative of a metabolically over activated yet energetically compromised state. By restoring Ca2⁺ homeostasis and restraining LDHA driven glycolytic flux, AREG shifts energy metabolism toward a more balanced, OXPHOS supported profile, resembling the metabolic ‘quietness’ seen in embryos with superior developmental potential [44, 48–50]. When exogenous AREG, a ligand of the EGFR, is added to the culture system, it activates EGFR and upregulates REM2, thereby inhibiting VGCCs, lowering cytosolic Ca2+, stabilizing calcium homeostasis, and promoting ATP generation. Consequently, excessive LDHA expression and pyruvate-to-lactate shunting are restrained, pan-lactylation is attenuated, and OXPHOS is strengthened, ultimately remodeling early embryonic energy metabolism and improving the developmental potential of aged embryos. Nevertheless, important questions and limitations remain. At the mechanistic level, it will be important to elucidate the precise way in which REM2 inhibits VGCCs and how disrupted Ca2+ homeostasis leads to LDHA upregulation. Our current data establish a causal link between Ca2+ imbalance and increased LDHA protein levels, but do not yet distinguish whether Ca2+ signaling acts via transcriptional control of the LDHA promoter, altered mRNA stability, or other post-transcriptional mechanisms. It also remains to be determined why, despite LDHA upregulation and enhanced glycolytic flux, aged embryos still fail to fully compensate for the energy deficit, and how lactate-driven increases in pan-lactylation quantitatively and qualitatively influence early embryonic gene regulation and cell-fate decisions. Direct assessment of LDHA promoter activity or mRNA turnover in 2‑cell embryos will require technically challenging low‑input reporter and RNA‑decay assays. We will further explore it in future research. With respect to the model, extrapolation from mice to humans requires validation, and the lower oocyte yield in aged patients may constrain clinical implementation; nevertheless, we will actively advance the corresponding clinical trial. In parallel, the long-term effects of optimized culture on potential offspring—including neonatal health, subsequent development, and adult outcomes—require systematic evaluation. Despite these limitations, our findings provide a feasible path to mitigating, and potentially reversing, age-related declines in embryonic developmental potential. Conclusion In summary, supplementing embryo culture with 100 nM AREG enhances early embryonic development by activating EGFR, upregulating REM2, and inhibiting VGCC‑mediated Ca2+ influx. This stabilizes intracellular Ca2+, elevates ATP, suppresses excessive LDHA, reduces pyruvate‑to‑lactate conversion and pan‑lactylation, and strengthens OXPHOS, collectively remodeling energy metabolism and improving developmental potential. These findings suggest that targeted AREG supplementation could improve ART outcomes in women of advanced maternal age. Supplementary Information Below is the link to the electronic supplementary material. Supplementary file1 (DOCX 61267 KB) Supplementary file2 (DOCX 33 KB) Authors' contributions Zhiguo Zhang, Beili Chen and Tingting Ye designed the experiments and revised the manuscript. DandanYang performed the experiment and wrote the manuscript. Menghan Chai and Kuangjian Zhang performed the experiment and verified the data. Qiqi Zhang and Chao Zhang collected data from patients. Huijuan Zou and Weiwei Zou participated in the revision of the manuscript. Lanxin Xie and Ming Xiong reviewed the data statistic. Funding This work was supported by the National Key Research and Development Program of China (No. 2022YFC2703000 to Z.G.Z.), the Research Fund of Anhui Institute of Translational Medicine (No.2024zh-03 to Z.G.Z.), the National Natural Science Foundation of China (No. 82001516 to B.L.C.), the Open Fund Project of the Engineering Research Center of Biopreservation and Artificial Organs, Ministry of Education. Data availability All relevant data are included within this article, or are available freely from the corresponding authors upon reasonable request. Declarations Ethics approval This study received approval from the Ethics Committee of Anhui Medical University (No. 20240111). All animal procedures were conducted in accordance with protocols approved by the Animal Ethics Committee of Anhui Medical University (No: LLSC20242465). Competing interests The authors have no relevant financial or non-financial interests to disclose. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Dandan Yang, Menghan Chai and Kuanjian Zhang contributed equally to this work. Contributor Information Tingting Ye, Email: 1467492113@qq.com. Beili Chen, Email: cbl0118@126.com. Zhiguo Zhang, Email: zzg_100@163.com. References Associated Data Supplementary Materials Supplementary file1 (DOCX 61267 KB) Supplementary file2 (DOCX 33 KB) Data Availability Statement All relevant data are included within this article, or are available freely from the corresponding authors upon reasonable request.